1. Scrip
  2. >>Business
  3. >>Deals

Gossamer Partners With Chiesi To Accelerate Seralutinib Development

Cash Will Fund Trial In Second, Larger Indication

 
• By Mandy Jackson

Already in Phase III for PAH, Gossamer said it can take seralutinib into Phase III for PH-ILD at least four years earlier than planned under its alliance with respiratory disease expert Chiesi.

Pulmonary hypertension is a cardiovascular condition characterized by high blood pressure in the pulmonary arteries 3D rendering
Topline Phase III data in PAH are expected in Q4 2025 • Source: Shutterstock

Gossamer Bio, Inc. is testing its inhaled kinase inhibitor seralutinib in a Phase III clinical trial as a potential disease-modifying treatment for pulmonary arterial hypertension (PAH), but has its eyes on the larger, less crowded market of pulmonary hypertension associated with interstitial lung disease (PH-ILD). Now, after signing a deal with Chiesi Farmaceutici S.p.A., Gossamer has the resources to begin a Phase III trial in PH-ILD at least four years sooner than planned.

Key Takeaways

  • Gossamer, down to its last drug candidate, sees a path to blockbuster status with seralutinib and can expand from PAH into a second indication of PH-ILD...

San Diego-based Gossamer and the Italian respiratory and rare disease specialist Chiesi announced their global collaboration and license agreement on 6 May for the development and commercialization of seralutinib in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.